A Combination of Abraxane and Cisplatin in Metastatic Breast Cancer

A Single Institutional Phase II Clinical Trial of Abraxane Combined With Cisplatin in Metastatic Breast Cancer

This phase II trial on the assumption that abraxane and cisplatin combination therapy is efficacy in metastatic breast cancer.

Study Overview

• Status: Completed
• Conditions: Metastatic Breast Cancer
• Intervention / Treatment: Drug: Abraxane and Cisplatin combination

Detailed Description

The rationales for the combination of Abraxane and cisplatin include that either drug has antitumor activity; they have different mechanisms; no cross-resistance are documented between them, and there have been some preclinical evidences indicating synergistic effects between the two agents. This phase II study will be undertaken to evaluate combination of cisplatin and weekly abraxane in terms of efficacy and safety in MBC patients.

• Study Type: Interventional
• Enrollment (Actual): 73
• Phase: Phase 2

Contacts and Locations

Study Locations

• China
  • Shanghai, China, 200032
    • Fudan University Cancer Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 70 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Female

Description

Inclusion Criteria:

• Subject must fulfill all of the following conditions or characteristics in order to be considered for study enrollment:

  1. Written informed consent prior to study specific screening procedures, with the understanding that the patient has the right to withdraw from the study at any time without prejudice.
  2. At least one measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST).
  3. Histopathologically or cytologically confirmed breast cancer.
  4. Female at an age of ≥18 years.
  5. Prior taxane or platinum treatment allowed. However, the drug interval should be longer than 12 months in adjuvant/neo-adjuvant setting and three months in MBC patients who have obtained ORR with taxane- or platinum-containing regimens.

  6. The lab values within 2 weeks prior to trial should meet:

     • PLT ≥100,000/mm3
     • ANC≥2000/mm3
     • HB≥80g/L
     • Total bilirubin < upper limit of normal level（UNL, < 1.5 x UNL for patients with liver metastasis)
     • ALT/AST < 1.5 x UNL (< 2.5 x UNL for patients with liver metastasis)
     • AKP < 5 x UNL (except for patients with bone metastasis)
     • Serum creatinine < UNL
  7. ECOG performance status of 0, 1 or 2.
  8. A life expectancy of more than 3 months.

Exclusion Criteria:

1. Pregnant or breast-feeding women.
2. Positive serum pregnancy test.
3. Unwilling to use a medically acceptable form of contraception, except for those who were surgically sterile or at least 1 year postmenopausal.
4. Uncontrolled brain metastases. Patients with brain metastases must be locally treated and the disease must be stable for at least one month at the time of enrolling.
5. Meningeal metastases.
6. Radiotherapy within the 4 weeks preceding study treatment start.
7. Incomplete recovery from the effects of major surgery.
8. Prior hormonal treatment allowed but must be discontinued 14 days prior to study entry.
9. Participation in any investigational drug study within 4 weeks preceding treatment start.
10. Blood transfusions or growth factors to aid hematological recovery within 2 weeks prior to study treatment start.
11. Significant medical condition that would make treatment or follow-up on this protocol difficult or problematic in the opinion of the treating oncologist.
12. Concurrent other malignancy at other sites or previous other cancer within the last 5 years, with the exception of adequately treated in situ carcinoma of cervix uteri or basal or squamous cell carcinoma of the skin or a contralateral breast cancer.
13. Serious uncontrolled intercurrent infections.
14. Poor compliance.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Abraxane and Cisplatin combination	Drug: Abraxane and Cisplatin combination; Abraxane will be given at 125 mg/m2, venous infusion within 30 minutes, administered on days 1, 8 and 15. Cisplatin at 75mg/m2, venous infusion for 120 minutes, will be administered on day 1.; Other Names: Abraxane; Cisplatin

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Overall response rates (ORR) of abraxane and cisplatin combination therapy	2months

Secondary Outcome Measures

Outcome Measure	Time Frame
Progression free Suivial (PFS)	6 months
Number of adverse event	2 months
Overrall Survival (OS)	12 months

Collaborators and Investigators

• Sponsor: Fudan University
• Investigators: Study Chair: Xichun Hu, Fudan University

Publications and helpful links

General Publications

• Li Y, Zhao Y, Gong C, Xie Y, Hu X, Zhang J, Wang L, Zhang S, Cao J, Tao Z, Wang B. Cisplatin shows greater efficacy than gemcitabine when combined with nab-paclitaxel in metastatic triple-negative breast cancer. Sci Rep. 2019 Mar 5;9(1):3563. doi: 10.1038/s41598-019-39314-y.
• Tang LC, Wang BY, Sun S, Zhang J, Jia Z, Lu YH, Di GH, Shao ZM, Hu XC. Higher rate of skin rash in a phase II trial with weekly nanoparticle albumin-bound paclitaxel and cisplatin combination in Chinese breast cancer patients. BMC Cancer. 2013 May 9;13:232. doi: 10.1186/1471-2407-13-232.

Study record dates

Study Major Dates

• Study Start: June 1, 2010
• Primary Completion (Actual): June 1, 2011
• Study Completion (Actual): November 1, 2011

Study Registration Dates

• First Submitted: June 23, 2010
• First Submitted That Met QC Criteria: June 23, 2010
• First Posted (Estimate): June 24, 2010

Study Record Updates

• Last Update Posted (Estimate): August 7, 2012
• Last Update Submitted That Met QC Criteria: August 5, 2012
• Last Verified: August 1, 2012

More Information

Terms related to this study

• Keywords: metastatic breast cancer; combined chemotherapy
• Additional Relevant MeSH Terms: Skin Diseases; Neoplasms; Neoplasms by Site; Breast Diseases; Breast Neoplasms; Molecular Mechanisms of Pharmacological Action; Antineoplastic Agents; Tubulin Modulators; Antimitotic Agents; Mitosis Modulators; Antineoplastic Agents, Phytogenic; Paclitaxel; Cisplatin; Albumin-Bound Paclitaxel
• Other Study ID Numbers: Fudan BR2010-02